MRNA in the 13F filings
Moderna Inc · CUSIP 60770K107
- Quarter end
- 30 Sep 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 31 Oct 2024
- Managers listing it
- 12
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q2 2024 and Q3 2024; 7 listed it in both
- Shares listed
- 72,541,879
- combined, among listed positions
- Reported value
- $4.8bn
- combined, at the quarter end
Among the 94 comparable managers: 9 buyers (opened or added shares) and 4 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing MRNA in Q3 2024
12 of 12 holders
Largest increases and reductions, by shares
Increases
- Invesco Ltdexisting position · 4,026,604 shares now+1,486,333
- Wellington Management Group LLPexisting position · 5,224,685 shares now+906,114
- Voloridge Investment Management LLCnew position · 594,828 shares now+594,828
- Two Sigma Advisers LPnew position · 356,500 shares now+356,500
- Woodline Partners LPnew position · 131,555 shares now+131,555
Reductions
- Fidelity (FMR LLC)existing position · 17,382,165 shares now-3,779,120
- Baillie Gifford & Coexisting position · 42,458,083 shares now-990,958
- PDT Partners LLCexisting position · 21,300 shares now-18,390
New positions and exits
New (3)
Exited (1)
- Capital World Investorswas $435m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2018 | 2 | $287m | n.a. | n.a. |
| Q1 2019 | 3 | $688m | n.a. | n.a. |
| Q2 2019 | 2 | $167m | n.a. | n.a. |
| Q3 2019 | 2 | $126m | n.a. | n.a. |
| Q4 2019 | 5 | $449m | n.a. | n.a. |
| Q1 2020 | 8 | $1.0bn | n.a. | n.a. |
| Q2 2020 | 9 | $3.1bn | n.a. | n.a. |
| Q3 2020 | 6 | $3.1bn | n.a. | n.a. |
| Q4 2020 | 16 | $4.4bn | n.a. | n.a. |
| Q1 2021 | 18 | $8.0bn | n.a. | n.a. |
| Q2 2021 | 22 | $18.4bn | n.a. | n.a. |
| Q3 2021 | 27 | $27.6bn | n.a. | n.a. |
| Q4 2021 | 20 | $17.2bn | n.a. | n.a. |
| Q1 2022 | 16 | $11.8bn | n.a. | n.a. |
| Q2 2022 | 19 | $10.2bn | n.a. | n.a. |
| Q3 2022 | 22 | $8.4bn | n.a. | n.a. |
| Q4 2022 | 20 | $13.0bn | n.a. | n.a. |
| Q1 2023 | 17 | $11.2bn | n.a. | n.a. |
| Q2 2023 | 15 | $8.9bn | n.a. | n.a. |
| Q3 2023 | 12 | $7.2bn | n.a. | n.a. |
| Q4 2023 | 8 | $6.9bn | 5 | 5 |
| Q1 2024 | 7 | $7.6bn | 3 | 5 |
| Q2 2024 | 13 | $9.5bn | 9 | 4 |
| Q3 2024 | 12 | $4.8bn | 9 | 4 |
| Q4 2024 | 15 | $3.1bn | 13 | 3 |
| Q1 2025 | 11 | $2.0bn | 9 | 4 |
| Q2 2025 | 10 | $2.0bn | 7 | 3 |
| Q3 2025 | 9 | $1.2bn | 5 | 4 |
| Q4 2025 | 10 | $2.5bn | 16 | 20 |
| Q1 2026 | 9 | $4.8bn | 17 | 19 |
| Q2 2026 | 9 | $8.0bn | 17 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MRNA and GILD →MRNA and AMGN →MRNA and ARGX →Choose a stock to compare with MRNA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MRNA, latest filings →Back to the 13F Explorer →